Prostate Cancer

Analyses of data from men in the intervention (screening) arm of the Prostate, Lung, Colorectal, and Ovary (PLCO) study show that prostatic biopsy is not associated with an increased risk of early mortality.

Some men with low-risk prostate cancer who are being managed by active surveillance can have their PSA levels measured every 6 months instead of every 3 months, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.

In men with diabetes who are diagnosed with prostate cancer, use of metformin reduces both cancer-specific and all-cause mortality, and the treatment benefits increase with increasing cumulative duration of exposure to the drug, according to the results of a retrospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.

The data are not convincing that one form of newer technology is superior to the traditional lower-cost prostate cancer treatments they replace (eg, robotic vs. open prostatectomy and photon vs. proton radiation).

Men plan to continue getting PSA tests despite the U.S. Preventive Services Task Force’s recommendation against screening, but just over one-third of men report shared decision making for screening with their physician, according to findings from two recently published studies.

Nerves play a critical role in both the development and spread of prostate tumors, report researchers at Albert Einstein College of Medicine of Yeshiva University, Bronx, NY.

High blood concentrations of omega-3 fatty acids are associated with an increased risk of prostate cancer, results of a recently published study show.

Adherence to a series of lifestyle recommendations leads to a significantly decreased risk of highly aggressive prostate cancer, according to a recent study.

Danil V. Makarov, MD, MHS, presents the take home messages on outcomes analysis.

A study of more than 1,800 men ages 52 to 62 years suggests that African-Americans diagnosed with very low-risk prostate cancers are much more likely than Caucasian men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.

Jay D. Raman, MD, presents the take home messages on prostate cancer from the AUA annual meeting in San Diego.

Observation appears to be safe and more cost effective than immediate treatment for many men with low-risk, localized prostate cancer, according to a recent study from Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston.

Early exposure to bisphenol A (BPA) leads to an increased cancer risk in an animal model of human prostate cancer, according to new research findings from the University of Illinois at Chicago.

“Our group all felt that we were caught off guard," said one urologist about the AUA's new prostate cancer screening guideline.

A relatively new imaging system demonstrates a higher capacity for mapping recurrent prostate cancer than integrated positron emission tomography and computed tomography, researchers recently reported at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Vancouver, British Columbia.

Men with prostate cancer may significantly improve their survival chances with a simple change in their diet, according to a recent study.

A new AUA guideline on the early detection of prostate cancer is a PSA-focused, evidence-based guideline intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening in order to reduce prostate cancer mortality, said H. Ballentine Carter, MD, at the AUA annual meeting in San Diego.

Results from the primary endpoint analysis in a phase III randomized, placebo-controlled study showed that intravenous radium Ra 223 dichloride (Xofigo), an alpha-particle-emitting radiotherapeutic agent and calcium mimetic that binds to newly formed bone stroma, significantly improved overall survival in castration-resistant prostate cancer patients with bone metastases.

The AUA has released its first-ever clinical practice guideline for castration-resistant prostate cancer, and all urologists who care for men with advanced prostate cancer should familiarize themselves with its contents, said Michael S. Cookson, MD, who presented the new guideline at the AUA annual meeting in San Diego.

A novel class of drug that disrupts androgen receptor signaling may some day provide a new therapeutic option for patients with advanced prostate cancer who fail androgen blockade.

Researchers using next-generation genomic analysis have determined that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression.

The recent completion of the AUA’s Guideline on Castration-Resistant Prostate Cancer was not only timely but also very important for those of us treating these patients.

A recent analysis has found a link between exposure to the herbicide known as Agent Orange and lethal forms of prostate cancer among U.S. veterans.

In what is being called the largest clinical trial to examine the efficacy of poly(ADP-ribose) polymerases (PARP) inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced forms of both prostate and pancreatic cancer.

Intensity-modulated radiation therapy may not be more effective than conformal radiation therapy in patients who have undergone radical prostatectomy, say researchers from the University of North Carolina, Chapel Hill.

Data from a third planned interim analysis of a phase III trial are consistent with earlier results supporting the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for chemotherapy-naïve men with metastatic castration-resistant prostate cancer.

Three urologists discuss how they review prostate cancer treatment options with their patients.

Robot-assisted laparoscopic prostatectomy in patients with intermediate- or high-risk cancers achieves outcomes similar to those seen with the open procedure, say researchers from Vanderbilt University, Nashville, TN.

The clinical advantages of adjuvant or salvage radiation therapy in patients treated for prostate cancer by radical prostatectomy is currently a much-debated issue and is frequently decided for the individual patient. New evidence, however, seems to indicate that secondary radiation therapy (RT) does not negatively affect urinary continence.

A new study has confirmed that a genetic test that measures cell cycle progression (CCP) can be a useful tool for predicting which patients will have prostate cancer recurrence, especially when combined with existing information from laboratory and pathology tests.